CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 473 participants.
Also called NCT03636269
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 473 participants
- Sponsor
- Registry
-
NCT03636269
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Canada, Czechia, Germany, Hungary, New Zealand, Poland, South Korea, Taiwan, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03636269. Randomized; triple masking; primary purpose treatment. Start 2018-07-17 (actual); primary completion 2020-03-30 (actual). Results posted on 2022-04-26.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
- Acronym
- KALM-2
- Condition
- Uremic Pruritus
- Intervention (Drug)
- CR845 0.5 mcg/kg
- Intervention (Drug)
- Placebo
- Lead sponsor
- Cara Therapeutics, Inc.
Record details
- Record id
cardio:ct-nct03636269- Content hash
87a50e6f36eb68ffba68bc57d0e452b23ac29ebdd3678a93e11caed45b2b8331